Trial intelligence / Profile preview

FOLFOX-4 Duration and Bevacizumab in Adjuvant Therapy for Stage II/III Colon Cancer

2007-000354-31Phase 3Active

Sponsor: Fondazione Giscad per la Ricerca sui Tumori
Start: Nov 2007
Modality: Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised trial of oxaliplatin, fluorouracil, folinic acid and bevacizumab in colon cancer (2 arms), sponsored by Fondazione Giscad per la Ricerca sui Tumori. Primary endpoints: relapse free survival and overall survival. Started Nov 2007; status: active.

Drugs

oxaliplatinfluorouracilfolinic acidbevacizumab

Conditions

colon cancer

Beyond the preview

Go deeper on 2007-000354-31.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-000354-31.